Navigation Links
Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
Date:4/23/2013

(PRWEB) April 23, 2013

A recently released study from the University of California, Los Angeles showed evidence of increased pre-cancerous changes in diabetic patients using “Incretin Mimetics,” a type of Type-2 Diabetes medication, in which the drugs Byetta and Januvia both belong. Incretin is a natural hormone that your body produces to assist the release of insulin to lower blood sugar. Patients with Type-2 Diabetes have problems producing that hormone. Byetta and Januvia were created to put incretin mimetics into the body to act like incretin to prompt your pancreas to release the insulin when blood sugar is low (i). Visit the website of d’Oliveira and Associates for more information about these two drugs: Byetta and Januvia.

A study conducted by Alexandra Butler and Peter Butler of the University of California, Los Angeles tested twenty individuals with diabetes and showed a 40 percent increase in pancreatic cell growth (ii). The same study found that cell damage in the people treated with the type of therapy provided from Byetta and Januvia had the potential to evolve into cancer (ii).    Public Citizen, a Washington-based public advocacy group, stated that this information is in accord with the increasing reported to the U.S. Food and Drug Administration (FDA) that there is a higher correlation between patients with pancreatic cancer and those that are using these types of drugs, as compared to other diabetes drugs (ii).

An additional study published by the Journal of American Medical Association (JAMA) Internal Medicine discovered that Januvia and Byetta may double the patients’ risk of pancreatitis. The JAMA study showed that patients hospitalized with pancreatitis were twice as likely to be using Januvia or Byetta when compared to those that did not have pancreatitis. This is the first study to have solid numbers to prove the hazards of Byetta and Januvia (iii).

The FDA has been aware of the effects and how these drugs may damage the pancreas since 2009 for Januvia (iv) and since 2007 for Byetta (v). After pancreatitis caused six deaths, the FDA increased the warnings on Byetta’s drug label even though they could not determine the cause of pancreatitis in four of the death. However, the manufacturers of these drugs are still making a profit. Merck, Januvia’s manufacturer, had reported $4.1 billion in 2012 worldwide sales. Bristol-Myers, Byetta’s manufacturer reported that Byetta and its longer-acting version, Bydureon, had made $227 million in total sales in 2012 (ii).

Attorney Paul d’Oliveira stated that “I feel this new study sheds some light on whether these type 2 diabetes drugs are actually as safe as the manufacturers say they are. Hopefully this new study will force these manufacturers to take a closer look at the adverse reaction reports and consider whether these drugs should be pulled from the market.”

If after using Januvia or Byetta and find that you or someone you know has developed pancreatitis or pancreatic cancer, d'Oliveira & Associates recommends that anyone afflicted do thier research to find the best Januvia and/or Byetta lawyer you can as you may only have one chance to get justice. d'Oliveira & Associates is working with some of the more experienced dangerous durgs attorneys in the country who are filing lawsuits, and there is no fee until a settlement or award is obtained.

For a free consultation, call 1-800-992-6878 or visit their website at dmlaw.com.

Sources:
(i) http://diabetes.webmd.com/incretin-mimetics-for-type-2-diabetes
(ii) http://www.bloomberg.com/news/2013-03-22/diabetes-drugs-may-cause-damage-to-pancreas-study-finds.html
(iii) http://archinte.jamanetwork.com/article.aspx?articleid=1656537#RESULTS
(iv) http://www.fda.gov/downloads/Drugs/DrugSafety/UCM204269.pdf
(v) http://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf

Read the full story at http://www.prweb.com/releases/2013/4/prweb10638086.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
2. Blood Test Might Spot Pancreatic Cancer Early, Study Finds
3. New metabolite-based diagnostic test could help detect pancreatic cancer early
4. Dana-Farber Scientists find potential loophole in pancreatic cancer defenses
5. Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
6. IU researchers receive $3.2 million to develop, improve therapies for pancreatic cancer
7. Bitter melon juice prevents pancreatic cancer in mouse models
8. Cleveland Clinic study shows bariatric surgery restores pancreatic function by targeting belly fat
9. Molecular master switch for pancreatic cancer identified, potential predictor of treatment outcome
10. Clinical trial looks to improve pancreatic cancer survival rates
11. Blood Test Might Help Guide Pancreatic Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... San Francisco dentist, ... Element, the latest in 3-D scanning device which is capable of taking digital impressions ... advances in dentistry, such as CAD CAM restorations , in terms of speed, ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go this Valentine's Day? Well, ... door for a romantic, lobster feast in the comfort of your own home. Lobster ... The dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India , January 16, ... Market Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry ... and is expected to reach $4,531 million by 2022, registering a CAGR of ... accounted for more than one-third share of the global volume in 2015. ... ...
(Date:1/16/2017)... 2017 Bill is an internationally experienced medical ... and leadership positions with global medical device companies, including Smith & ... of launching new products and building successful businesses in the sector ... Africa and North America . ... Educated at the University ...
(Date:1/16/2017)... Calif. , Jan. 16, 2017  Rigel Pharmaceuticals ... January 3, 2017 and January 16, 2017 the Compensation ... of inducement stock options to purchase an aggregate of ... These awards were granted pursuant to the Rigel Pharmaceuticals, ... to the new employees entering into employment with Rigel, ...
Breaking Medicine Technology: